March 18 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved UK-based Orchard Therapeutics' gene therapy for the treatment of children with a rare hereditary disease called metachromatic leukodystrophy (MLD). (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,656 JPY | +2.87% | +3.41% | +12.05% |
May. 07 | Kyowa Kirin's Profit Up 15% in Q1 | MT |
May. 06 | Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,772 PTS | +1.70% | +0.64% | - | ||
2,656 JPY | +2.87% | +3.41% | 9B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.05% | 9B | |
+15.54% | 78.51B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
+21.94% | 2.48B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- 4151 Stock
- News Kyowa Kirin Co. Ltd.
- US approves first gene therapy for rare genetic disease